<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Doses for parenteral antibiotics for the empiric treatment of community-acquired pneumonia in hospitalized children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Doses for parenteral antibiotics for the empiric treatment of community-acquired pneumonia in hospitalized children</h1>
<div class="graphic"><div class="figure"><div class="ttl">Doses for parenteral antibiotics for the empiric treatment of community-acquired pneumonia in hospitalized children</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent</td> <td class="subtitle1">Regimen<sup>[1,2]</sup></td> <td class="subtitle1">Comments</td> </tr> <tr> <td>Ampicillin</td> <td> <ul> <li>150 to 200 mg/kg per day in 4 divided doses (MAX 12 g/day)</li> </ul> </td> <td> </td> </tr> <tr> <td>Azithromycin</td> <td> <ul> <li>10 mg/kg once per day on days 1 and 2 of therapy (MAX 500 mg/day)</li> <li>5 mg/kg once per day on subsequent days of therapy (MAX 250 mg/day)</li> </ul> </td> <td> <ul> <li>Transition to oral therapy at 5 mg/kg per day as soon as clinically appropriate</li> </ul> </td> </tr> <tr> <td>Cefazolin</td> <td> <ul> <li>100 to 150 mg/kg per day in 3 divided doses (MAX 12 g/day)</li> </ul> </td> <td> <ul> <li>Limited data on doses &gt;100 mg/kg per day</li> </ul> </td> </tr> <tr> <td>Cefotaxime</td> <td> <ul> <li>150 mg/kg per day in 3 or 4 divided doses (MAX 8 g/day)</li> </ul> </td> <td> <ul> <li>The 4-dose regimen should be used for severe infection or substantial local penicillin resistance</li> </ul> </td> </tr> <tr> <td>Ceftaroline</td> <td> <ul> <li>Age ≥2 months and &lt;2 years: 8 mg/kg every 8 hours</li> <li>Age ≥2 and &lt;18 years: <ul> <li>Weight ≤33 kg: 12 mg/kg every 8 hours</li> <li>Weight &gt;33 kg: 400 mg every 8 hours or 600 mg every 12 hours</li> </ul> </li> <li>Age ≥18 years: 600 mg every 12 hours</li> </ul> </td> <td> <ul> <li>Experience with ceftaroline in children with documented MRSA infection is limited</li> </ul> </td> </tr> <tr> <td>Ceftriaxone</td> <td> <ul> <li>50 to 100 mg/kg per day in 1 or 2 divided doses (MAX 4 g/day)</li> </ul> </td> <td> <ul> <li>The 100 mg/kg per day dose should be used only if local rates of penicillin resistance to <em>Streptococcus pneumoniae</em> are substantial (eg, ≥25%)</li> <li>The 2-dose regimen should be used for severe infection or if local rates of penicillin resistance to <em>S. pneumoniae</em> are substantial (eg, ≥25%)</li> </ul> </td> </tr> <tr> <td>Clindamycin</td> <td> <ul> <li>30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 2.7 g/day)</li> </ul> </td> <td> </td> </tr> <tr> <td>Doxycycline</td> <td> <ul> <li>4 mg/kg per day in 2 divided doses (MAX 200 mg/day)</li> </ul> </td> <td> <ul> <li>Transition to oral therapy as soon as clinically appropriate</li> </ul> </td> </tr> <tr> <td>Erythromycin</td> <td> <ul> <li>20 mg/kg per day in 4 divided doses (MAX 4 g/day)</li> </ul> </td> <td> <ul> <li>Parenteral erythromycin is associated with phlebitis, prokinetic, and cardiotoxic effects (rare)</li> </ul> </td> </tr> <tr> <td>Levofloxacin</td> <td> <ul> <li>Age 6 months and &lt;5 years: 16 to 20 mg/kg per day in 2 divided doses</li> <li>Age ≥5 to 16 years: 8 to 10 mg/kg once per day (MAX 750 mg)</li> </ul> </td> <td> <ul> <li>Fluoroquinolones may prolong QTc interval; avoid use in patients with:<sup>[3]</sup> <ul> <li>Long QT syndrome</li> <li>Hypokalemia or hypomagnesemia</li> <li>Organic heart disease (eg, congestive heart failure; requiring a class Ia antiarrhythmic drug*, particularly quinidine)</li> <li>Concurrent use of other medications that prolong the QTc interval</li> </ul> </li> </ul> </td> </tr> <tr> <td>Linezolid</td> <td> <ul> <li>Age &lt;12 years: 10 mg/kg every 8 hours (MAX 600 mg/dose)</li> <li>Age ≥12 years: 600 mg every 12 hours</li> </ul> </td> <td> </td> </tr> <tr> <td>Nafcillin</td> <td> <ul> <li>150 to 200 mg/kg per day in 4 or 6 divided doses (MAX 12 g/day)</li> </ul> </td> <td> </td> </tr> <tr> <td>Penicillin G</td> <td> <ul> <li>For therapy: 200,000 to 250,000 units/kg per day in 4 or 6 divided doses (MAX 24 million units/day)</li> </ul> </td> <td> </td> </tr> <tr> <td>Vancomycin</td> <td> <ul> <li>40 to 60 mg/kg per day in 3 or 4 divided doses (MAX 4 g/day)<sup>¶</sup></li> </ul> </td> <td> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is meant for use with UpToDate content on the treatment of community-acquired pneumonia in children. Refer to related UpToDate content for details about choice of therapy. Consultation with a specialist in pediatric infectious diseases is suggested for children with severe hypersensitivity to beta-lactam antibiotics (eg, penicillins and cephalosporins). The recommended doses are for children with normal renal function.</div><div class="graphic_footnotes"><p>MAX: maximum dose; MRSA: methicillin-resistant <em>Staphylococcus aureus</em>.</p>
<p>* Class Ia antiarrhythmic drugs include quinidine, ajmaline, disopyramide, and procainamide.</p>
¶ Alternative dosing is suggested for clinicians/institutions who follow AUC-guided therapeutic monitoring for vancomycin for serious MRSA infections as suggested by <a href="https://www.idsociety.org/practice-guideline/vancomycin" target="_blank">consensus guidelines</a><sup>[4]</sup>; this strategy requires input from a clinical pharmacist, who will provide recommendations for initial dosing. Refer to UpToDate content on invasive staphylococcal infections in children for details of trough-guided and AUC-guided vancomycin dosing.</div><div class="graphic_reference">References:
<ol>
<li>American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.876.</li>
<li>Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.</li>
<li>American Academy of Pediatrics. Fluoroquinolones. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.864.</li>
<li>Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.</li>
</ol></div><div id="graphicVersion">Graphic 127763 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
